Design, synthesis and pharmacological tests of leukotrienes A4 hydrolase inhibitors as potential targets of interest in cancer treatment – Lab Report Example

Design, synthesis and pharmacological tests of leukotrienes A4 hydrolase inhibitors as potential targets of interest in cancer treatment. Experimental Part
(E)-Resveratrol is a naturally occurring, potent LTA4 hydrolase inhibitor of high medical importance. Being based on stilbene skeleton, resveratrol can exist as both cis-(Z) and trans-(E) isomers, being the trans isomer the most commonly found in nature (Romero-Perez et al, 1996). Unfortunately, due to its low quantities in natural sources it cannot be obtained in large amounts by extraction from plants, such as Vitis vinifera. Therefore, many synthetic pathways were developed to synthesize this highly promising compound. (Farina, Guiso, and Marra, 2002).
One of the most efficient ways to achieve (E)-resveratrol is by employing the Heck reaction. The process is highly advantageous as it produces only the desired product in exceptional 99% yield:
Scheme 1: Synthesis of (E)-resveratrol using Heck reaction
As it is seen on the scheme 1, the starting 3,5-diacetoxy-stirene (1) was coupled with the para-iododerivative (2). Deacetilation of the formed stilbene derivative afforded the desired isomer of resveratrol.
The starting material (1) was prepared through the Wittig reaction followed by subsequent acetylation of the produced phenol as can be illustrated on the following diagram.
Scheme 2: Preparation of 3,5-diacetoxy-stirene (1)
While addressing on the topic of trans-resveratrol, the research does not make any contribution in the area of cis-resveratrol synthesis and application. (Farina, Guiso, and Marra, 2002).
To fill that gap, it is worth mentioning other methods of resveratrol synthesis. For example, Roberti, et al. (2003) synthesised a series of cis- and trans-resveratrol (Scheme 3) derivatives using the following Wittig reaction.
Scheme 3: Synthesis of stilbene derivatives
The groups marked as “R” are both silicon and carbon containing ethers. The silicon containing groups were further removed and the ability to induce apoptosis in cells of HL60 promyelocytic leukemia as well as cell growth inhibition properties of produced cis and trans-resveratrol derivatives were investigated. In most cases trans isomers were less effective than their cis counterparts. It was also established that the following two products stand out for showing the best results in the mentioned tests.
Scheme 4: Highly promising cis-Resveratrol derivatives
Comparing the accumulated results the authors concluded that structural changes in the stilbene backbone will undeniably lead to the production of powerful apoptosis-reducing agents.
The described research takes the concept of resveratrol based drugs to a new level, but do not mention the poor stability of cis-resveratrol (4). The information about cis-resveratrol is not as abundant as it is for trans isomer. Cis-resveratrol has shown antioxidant proterties, antiplatelet properties and affect cytoplasmic calcium levels in vascular smooth muscle cells Cis-resveratrol (4) has also shown to inhibit kinase activity, a factor related to cancer (Jayatilake et al., 1993) and has a significant modulatory effect on the nuclear factor kappa B signaling pathway (Leiro et al, 2005) and, consequently, an important antioxidant role that may partially explain the cardioprotective effects attributed to long-term moderate red wine consumption. That was the main reason for our design of a cis-resveratrol analogue (5) by modulative pharmacomodulation. (Scheme 5).
Scheme 5: cis-resveratrol (4) and its analogue (5) produced by modulative pharmacomodulation.
The compound preserves cis-resveratrol’s essential structural requirements and does not have the possibility of isomerization like it happens with natural cis-resveratrol (Trela and Waterhouse, 1996). For the synthesis of the resveratrol analogue (5), we need to prepare the corresponding nitro derivative (6) from the respective aldehyde (7) using the methodology developed by Dauzone (1986) as described in scheme 6.
Scheme 6
In order to prepare compound 5 we need to perform the Suzuki-Miyaura condensation (Beaumard et al., 2009) as descrived in scheme 7.
Scheme 7
After treatment of the nitro derivative 9 with sodium azide in DMSO (Quiclet and Zard, 2005) and deprotection, we should be able to obtain the desired compound 5 (scheme 8).
Scheme 8
MTT assay:
To asses cell growth inhibition properties MTT assay will be conducted. This colorimetric test is possible to apply in this particular case as LTA4H is an enzyme that reduces MTT. In order to do that 96-well plates will be populated with studied cancer cells(5000/well). To produce consistent results, six measurements should be done, repeating each concentration three times. At 370C MTT (5 mg/ml) for 4h will be added to the cells grown in various experimental conditions. As a consequence, purple formizan will be accumulated by reduction of MTT in the mitochondria of the living cells. Formisan is stabilised by DMSO. The amount of reduced MTT provides the information about the amount of viable cells and, therefore, effectiveness of the drug and cell proliferation.
The obtained formazan in its crystal state will be solubilized with DMSO and the absorbance measured at 570 nm using a Dynatech MR 5000 spectrometer. As this type of spectrometer is designed for 96-well plates it is possible to do all the measurements from 1.7 to 2.2 seconds depending on its input parameters.
Acetic anhydride
Dimethyl sulfoxide
((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
Beaumard F., Dauban P., Dodd R.H. 2009, One-pot double Suzuki-Miyaura couplings: rapid access to nonsymmetrical tri(hetero)aryl derivatives. Org. Lett., , 11(8),  pp. 1801-1804
Bonini, C. and Righi, G., 2002. A critical outlook and comparison of enantioselective oxidation methodologies of olefins. Tetrahedron, 58, pp.4981-5021.
Byrum, R.S., Goulet, J.L., Snouwaert, J.N, Griffiths, R.J. and Koller, B.H., 1999. Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice. Journal of Immunology.163, pp.6810-9.
Cai, Y.J., Wei, Q. Y., Fang, J. G., Yang, L., Liu, Z.L., Wyche, J.H. and Han, Z., 2004. The 3,4-Dihydroxyl Groups are Important for trans-Resveratrol Analogs to Exhibit Enhanced Antioxidant and Apoptotic Activities. Anticancer Research. 24. pp.999-1002.
Chen, X.W., Serag, E.S., Sneed, K.B. and Zhou, S.F., 2011. Herbal bioactivation, molecular targets and the toxicity relevance. Chem Biol Interact. 192, pp.161-76.
Chen, X., Wang, S., Wu, N. and Yang, C.S., 2004. Leukotriene A4 hydrolase as a target for cancer prevention and therapy. Curr Cancer Drug Targets. 4, pp.267-83.
Ciaccio, J.A., 1995. Diastereospecific Synthesis of an Epoxide. Journal of Chemical Education. 72 (11), pp.1037-1039.
Corey, E., Goto, G. and Marfat, A., 1980. Simple synthesis of the 11,12-oxido and 14,15-oxido analogs of leukotriene A and the corresponding conjugates with glutathione and cysteinylglycine, analogs of leukotrienes C and D. J. Am. Chem. Soc., 102 (21), p.6607.
Dauzonne, D.; Royer, R. 1986, A versatile synthesis of l-aryl-2-nitro-3-(3,4,5-tri-methoxypheny O-propenes as precursors of novel mescaline derivatives. Chem. Pharma. Bull., 34, pp. 1628-1633.
Davey, S., Feringa, B., Meetsma, A., Vicario, J. and Wiel, J., 2005. Organic & Biomolecular Chemistry, pp.28–30.
Davies, D.R., Mamat, B., Magnusson, O.T., Christensen, J., Haraldsson, M.H,, Mishra, R., Pease, B., Hansen, E., Singh, J., Zembower, D., Kim, H., Kiselyov, A.S., Burgin, A.B., Gurney, M.E. and Stewart, L.J., 2009. Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. J Med Chem, 52(15), pp.4694-715.
Di Gennaro, A., Kenne, E., Wan, M., Soehnlein, O., Lindbom, L. and Haeggström, J.Z., 2009. Leukotriene B4-induced changes in vascular permeability are mediated by neutrophil release of heparin-binding protein (HBP/CAP37/azurocidin). FASEB J. 23, pp.1750-7.
DuBois, R.N., 2003. Leukotriene A4 signaling, inflammation, and cancer. J Natl Cancer Inst. 95, pp.1028-9.
Farina, A., Guiso, M. and Marra, C., 2002. A new efficient resveratrol synthesis. Tetrahedron Letters, 43, pp.597–598.
Fourie, A.M., 2009. Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase. Curr Opin Investig Drugs, 10, pp.1173-82.

Fulda, S., 2010. Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov Today, doi:10.1016/j.drudis.2010.07.005.
Funk, C.,D., Rådmark, O., Fu, J.Y., Matsumoto, T., Jörnvall, H., Shimizu, T. and Samuelsson, B., 1987. Molecular cloning and amino acid sequence of leukotriene A4 hydrolase. Proc Natl Acad Sci USA, 84, pp.6677-81.
Goetzl, E.J., An, S. and Smith, W.L., 1995. Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. FASEB J, 9, pp.1051-8.
Guiso, M., Marra, C. and Farina, A., 2002. A new efficient resveratrol synthesis. Tetrahedron Letters, 43, pp.597–598.
Haeggström, J.Z. and Funk, C.D., 2011. Lipoxygenase and Leukotriene Pathways: Biochemistry,Biology, and Roles in Disease. Chem Rev, [Epub ahead of print]
Haeggström, J. and Wetterholm, A., 2002. Enzymes and receptors in the leukotriene cascade. Cell Mol Life Sci, 59, pp.742-53.
Hammock, D., Maxwell, J., Morisseau, C. and Williamson, C., 2000. Regio- and enantioselective hydrolysis of phenyloxiranes catalyzed by soluble epoxide hydrolase. Tetrahedron: Asymmetry, 11, pp.4451–4462.

Hashimoto, A., Endo, H., Hayashi, I., Murakami, Y., Kitasato, H., Kono, S., Matsui, T., Tanaka, S., Nishimura, A., Urabe, K., Itoman, M. and Kondo, H., 2003. Differential expression of leukotriene B4 receptor subtypes (BLT1 and BLT2) in human synovial tissues and synovial fluid leukocytes of patients with rheumatoid arthritis. J Rheumatol, 30, pp.1712-8.
Hicks, A., Monkarsh, S., Hoffman A. and Goodnow, R., 2007. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin Investig Drugs, 16, pp.1909-20.
Jayatilake, G., Jayasuriya, H. Lee, E., Koonchanok, N., Geahlen, R., Ashendel, C., McLaughlin, J.,Chang, C. 1993,. Kinase inhibitors from Polygonum cuspidatum.
J. Nat. Prod., 56, pp. 1805-1810.
Kim, G.Y., Lee, J.W., Cho, S.H., Seo, J.M. and Kim, J.H., 2009. Role of the low-affinity leukotriene B4 receptor BLT2 in VEGF-induced angiogenesis. Arterioscler Thromb Vasc Biol, 29, pp.915-20.
Lee, K.W., Bode, A.M. and Dong, Z., 2011. Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer, 11, pp.211-8.
Lee, T., Pandurangan, A., Selvaraj, M. and Seshadri, K., 2005. Highly selective synthesis of trans-stilbene oxide over mesoporous Mn-MCM-41 and Zr–Mn-MCM-41 molecular sieves. Microporous and Mesoporous Materials, pp.261–268.
Leiroa J., Arranza J., Fraizb N., Sanmartına M.., Quezadac E., Orallob F., 2005
Effect of cis-resveratrol on genes involved in nuclear factor
kappa B signalling. International Immunopharmacology 5, pp. 393–406
Li, H., Wu, W.,, Zheng, Z., Che, C., Li, Z., Xu, D., Ching, C., Wong, M., Ye, C., Sung, J., Cho, C. and Wang, M., 2010. 3,3′,4,5,5′-pentahydroxy-trans-stilbene, a resveratrol derivative, induces apoptosis in colorectal carcinoma cells via oxidative stress. European Journal of Pharmacology, 637 (1-3), pp.55-61.
Mueller, M.J., Blomster, M., Oppermann, U.C., Jörnvall, H., Samuelsson, B. and Haeggström, J.Z., 1996. Leukotriene A4 hydrolase: protection from mechanism-based inactivation by mutation of tyrosine-378. Proc Natl Acad Sci USA, 93, pp.5931-5.
Mueller, M.J., Andberg, M and Haeggström, J.Z., 1998. Analysis of the molecular mechanism of substrate-mediated inactivation of leukotriene A4 hydrolase. J Biol Chem, 273, pp.11570-5.
Murray, R. and Singh M. Synthesis of Epoxides Using Dimethyldioxirane: trans-Stilbene Oxide. Organic Syntheses,coll., 9, p.288 (1998); 74, p.91 (1997).
Oi, N., Jeong, C.H., Nadas, J., Cho, Y.Y., Pugliese, A., Bode, A.M. and Dong, Z., 2010. Resveratrol, a red wine polyphenol, suppresses pancreatic cancer by inhibiting leukotriene A4 hydrolase. Cancer Res, 70, pp.9755-64.
Orning, L., Gierse, J., Duffin, K., Bild, G., Krivi, G. and Fitzpatrick, F.A., 1992. Mechanism-based inactivation of leukotriene A4 hydrolase/aminopeptidase by leukotriene A4. Mass spectrometric and kinetic characterization. J. Biol. Chem., 267, pp.22733-9.
Orning, L., Jones, D.A. and Fitzpatrick, F.A., 1990. Mechanism-based inactivation of leukotriene A4 hydrolase during leukotriene B4 formation by human erythrocytes. J. Biol. Chem., 265, pp.14911-6.
Qiu, H., Gabrielsen, A., Agardh, H.E., Wan, M., Wetterholm, A., Wong, C.H., Hedin, U., Swedenborg, J., Hansson, G.K., Samuelsson, B., Paulsson-Berne, G. and Haeggström, J.Z., 2006. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA, 103, pp.8161-6.
QUICLET-SIRE, B.; ZARD, S..; 2005Novel and practical method for the efficient synthesis of 1,2,3-triazoles, Synthesis, 19, pp. 3319-3326
Rao, N.L., Dunford, P.J., Xue, X., Jiang, X., Lundeen, K.A., Coles, F., Riley, J.P., Williams, K.N., Grice, C.A., Edwards, J.P., Karlsson, L. and Fourie, A.M., 2007. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. J. Pharmacol. Exp. Ther., 321, pp.1154-60.
Roberti, M., Pizzirani, D., Simoni, D., Rondanin, R., Baruchello, R., Bonora C., Buscemi F., Grimaudo S. and Tolomeo M. 2003. Synthesis and Biological Evaluation of Resveratrol and Analogues as Apoptosis-Inducing Agents. J. Med. Chem., 46, pp.3546-3554.
Romero-Perez A., Lamuela-Raventos R., Waterhouse A., de la Torre-Boronat M. C., 1996. Levels of cis- and trans- Resveratrol and their Glucoside in White and Rose Vitis Vinifera Wines from Spain. J. Agric. Food. Chem., 44, pp. 2124-2128
Rudberg. P.C., Tholander, F., Thunnissen, M.M. and Haeggström, J.Z., 2002. Leukotriene A4 hydrolase/aminopeptidase. Glutamate 271 is a catalytic residue with specific roles in two distinct enzyme mechanisms. J. Biol. Chem., 277, pp.1398-404.
Rudberg, P.C., Tholander, F., Andberg, M., Thunnissen, M.M. and Haeggström, J.Z., 2004. Leukotriene A4 hydrolase: identification of a common carboxylate recognition site for the epoxide hydrolase and aminopeptidase substrates. J. Biol. Chem., 279, pp.27376-82.
Rudberg, P.C., Tholander, F., Thunnissen, M.M., Samuelsson, B. and Haeggstrom, J.Z., 2002. Leukotriene A4 hydrolase: selective abrogation of leukotriene B4 formation by mutation of aspartic acid 375. Proc Natl Acad Sci USA., 99, pp.4215-20.
Sala, A., Folco, G. and Murphy, R.C., 2010. Transcellular biosynthesis of eicosanoids. Pharmacol Rep., 62, pp.503-10.
Sinha, A.K., Kumar, V., Sharma, A., Sharma, A. and Kumar, R., 2007. Tetrahedron, 63, pp.11070–11077.
Szekeres, T., Fritzer-Szekeres, M., Saiko, P. and Jäger, W., 2010. Resveratrol and resveratrol analogues--structure-activity relationship. Pharm Res., 27, pp.1042-8.
Szekeres, T., Saiko, P., Fritzer-Szekeres, M., Djavan, B. and Jäger, W., 2011. Chemopreventive effects of resveratrol and resveratrol derivatives. Ann N Y Acad Sci., 1215, pp.89-95.
Tholander, F., Roques, B.P., Fournié-Zaluski, M.C., Thunnissen, M.M. and Haeggström, J.Z., 2010. Crystal structure of leukotriene A4 hydrolase in complex with kelatorphan, implications for design of zinc metallopeptidase inhibitors. FEBS Lett., 584, pp.3446-51.
Thunnissen, M.M., Andersson, B., Samuelsson, B., Wong, C.H. and Haeggström, J.Z., 2002. Crystal structures of leukotriene A4 hydrolase in complex with captopril and two competitive tight-binding inhibitors. FASEB J., 16, pp.1648-50.
Thunnissen, M.M., Nordlund, P. and Haeggström, J.Z., 2001. Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation. Nat Struct Biol., 8, pp.131-5.
Tobin, D.M., Vary, J.C., Ray, J.P., Walsh, G.S., Dunstan, S.J., Bang, N.D., Hagge, D.A., Khadge, S., King, M.C., Hawn, T.R., Moens, C.B. and Ramakrishnan, L., 2010. The LTA4H locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell., 140, pp.717-30.
Tong, W.G, Ding, X.Z., Talamonti, M.S., Bell, R.H. and Adrian, T.E., 2005. LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun., 335, pp.949-56.
Trela B. C. and Waterhouse A. L., 1996, Resveratrol: Isomeric Molar Absorptivities and Stability. J. Agric. Food Chem., 44, pp. 1253-1257
Wang, D. and Dubois, R.N., 2010. Eicosanoids and cancer. Nat Rev Cancer., 10, pp.181-93.